Sign Up Today and Learn More About Emalex Biosciences Stock
Invest in or calculate the value of your shares in Emalex Biosciences or other pre-IPO companies through EquityZen's platform.
Emalex Biosciences Stock (EMBI)
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders.
About Emalex Biosciences Stock
Founded
2018
Headquarters
Chicago, IL, US
Industries
Messaging and Telecommunications, Content and Publishing, Sports
Emalex Biosciences Press Mentions
Stay in the know about the latest news on Emalex Biosciences
Dopamine Receptor Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Dopamine Receptor Antagonists Therapeutics | DelveInsight
globenewswire • Mar 04, 2025
Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win
fiercebiotech • Feb 26, 2025
2024 BioTech Breakthrough Awards Program Celebrates Groundbreaking Biotechnology Innovators Around the World
globenewswire • Nov 19, 2024
Tourettes Syndrome Drugs Market size to grow by USD ...
finance • Jan 19, 2024
ADARx Pharmaceuticals, A Leader in Next Generation RNA ...
baincapital • Dec 24, 2023
Emalex Biosciences Management
Leadership team at Emalex Biosciences
Founder
Jeff Aronin
Chief Medical Officer
Atul Mahableshwarkar
Join now and verify your accreditation status to gain access to:
- Emalex Biosciences Current Valuation
- Emalex Biosciences Stock Price
- Emalex Biosciences Management
- Available deals in Emalex Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Emalex Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Emalex Biosciences Revenue and Financials
- Emalex Biosciences Highlights
- Emalex Biosciences Business Model
- Emalex Biosciences Risk Factors
- Emalex Biosciences Research Report from SACRA Research
Trading Emalex Biosciences Stock
How to invest in Emalex Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Emalex Biosciences through EquityZen funds. These investments are made available by existing Emalex Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Emalex Biosciences stock?
Shareholders can sell their Emalex Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
